Ticlopidine with Ginkgo biloba extract: A feasible combination for patients with acute cerebral ischemia

Thrombosis Research

Volumn 131, Issue 4, 2013, Pages

  Hong, Ji Man ^a   Shin, Dong Hoon ^b   Lim, Young Ae ^a   Lee, Jin Soo ^a   Joo, In Soo ^a  

^a Ajou University School of Medicine   (South Korea)

^b Gachon University   (South Korea)

Author keywords

antiplatelet; cerebral ischemia; combination; cytochrome; Ginkgo biloba extract; thiennopyridine

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; GINKGO BILOBA EXTRACT; THROMBIN; TICLOPIDINE;

ADULT; ALLELE; ARTICLE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ELECTRODE; FEASIBILITY STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ACUTE DISEASE; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BRAIN ISCHEMIA; FEMALE; GINKGO BILOBA; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLANT EXTRACTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84875741358     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.01.026     Document Type: Article

References (39)

1. M.J. Quinn, and D.J. Fitzgerald Ticlopidine and clopidogrel Circulation 100 1999 1667 1672
2. D.L. Bhatt, M.E. Bertrand, P.B. Berger, P.L. L'Allier, I. Moussa, and J.W. Moses Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J Am Coll Cardiol 39 2002 9 14
3. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, and C. Banuelos High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability Eur Heart J 25 2004 1903 1910
4. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
5. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, J.W. Jukema, and M.V. Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis Am Heart J 154 2007 221 231
6. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
7. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome p450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
8. W.C. Lau, P.A. Gurbel, P.B. Watkins, C.J. Neer, A.S. Hopp, and D.G. Carville Contribution of hepatic cytochrome p450 3a4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
9. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
10. B. Aleil, G. Rochoux, J.P. Monassier, J.P. Cazenave, and C. Gachet Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: A report of three cases J Thromb Haemost 5 2007 879 881
11. A. Wolak, G. Amit, C. Cafri, H. Gilutz, R. Ilia, and D. Zahger Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation Int J Cardiol 103 2005 293 297
12. G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, and A. Frangione Poor responsiveness to clopidogrel: Drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study J Am Coll Cardiol 50 2007 1132 1137
13. B. Ahlemeyer, and J. Krieglstein Neuroprotective effects of ginkgo biloba extract Cell Mol Life Sci 60 2003 1779 1792
14. S. Saleem, H. Zhuang, S. Biswal, Y. Christen, and S. Dore Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury Stroke 39 2008 3389 3396
15. K.H. Ryu, H.Y. Han, S.Y. Lee, S.D. Jeon, G.J. Im, and B.Y. Lee Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time Thromb Res 124 2009 328 334
16. Y.S. Kim, M.K. Pyo, K.M. Park, P.H. Park, B.S. Hahn, and S.J. Wu Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (egb 761) Thromb Res 91 1998 33 38
17. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci: A meta-analysis JAMA 304 2010 1821 1830
18. Y. Fukuuchi, H. Tohgi, T. Okudera, Y. Ikeda, Y. Miyanaga, and S. Uchiyama A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in japanese patients with noncardioembolic cerebral infarction Cerebrovasc Dis 25 2008 40 49
19. D. Sibbing, S. Braun, S. Jawansky, W. Vogt, J. Mehilli, and A. Schomig Assessment of adp-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 2008 121 126
20. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
21. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of cyp2c19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
22. T. Jernberg, C.D. Payne, K.J. Winters, C. Darstein, J.T. Brandt, and J.A. Jakubowski Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
23. S. Uchiyama, T. Nakamura, M. Yamazaki, Y. Kimura, and M. Iwata New modalities and aspects of antiplatelet therapy for stroke prevention Cerebrovasc Dis 21 Suppl. 1 2006 7 16
24. D.J. Angiolillo, S.B. Shoemaker, B. Desai, H. Yuan, R.K. Charlton, and E. Bernardo Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the optimizing antiplatelet therapy in diabetes mellitus (optimus) study Circulation 115 2007 708 716
25. S.R. Mehta, J.P. Bassand, S. Chrolavicius, R. Diaz, J.W. Eikelboom, and K.A. Fox Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
26. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, and D. Spriggs Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The gravitas randomized trial JAMA 305 2011 1097 1105
27. W.M. Clark, L.G. Rinker, N.S. Lessov, S.L. Lowery, and M.J. Cipolla Efficacy of antioxidant therapies in transient focal ischemia in mice Stroke 32 2001 1000 1004
28. K. Chandrasekaran, Z. Mehrabian, B. Spinnewyn, K. Drieu, and G. Fiskum Neuroprotective effects of bilobalide, a component of the ginkgo biloba extract (egb 761), in gerbil global brain ischemia Brain Res 922 2001 282 292
29. A.K. Dutta-Roy, M.J. Gordon, C. Kelly, K. Hunter, L. Crosbie, and T. Knight-Carpentar Inhibitory effect of ginkgo biloba extract on human platelet aggregation Platelets 10 1999 298 305
30. G.B. Kudolo, S. Dorsey, and J. Blodgett Effect of the ingestion of ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects Thromb Res 108 2002 151 160
31. G.B. Kudolo, W. Wang, J. Barrientos, R. Elrod, and J. Blodgett The ingestion of ginkgo biloba extract (egb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane b2 production in healthy volunteers J Herb Pharmacother 4 2004 13 26
32. A. Maeda, H. Ando, T. Asai, H. Ishiguro, N. Umemoto, and M. Ohta Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine Clin Pharmacol Ther 89 2011 229 233
33. C.L. Bennett, J.M. Connors, J.M. Carwile, J.L. Moake, W.R. Bell, and S.R. Tarantolo Thrombotic thrombocytopenic purpura associated with clopidogrel N Engl J Med 342 2000 1773 1777
34. W.K. Hass, J.D. Easton, H.P. Adams Jr., W. Pryse-Phillips, B.A. Molony, and S. Anderson A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine aspirin stroke study group N Engl J Med 321 1989 501 507
35. F.L. Paradiso-Hardy, C.M. Angelo, K.L. Lanctot, and E.A. Cohen Hematologic dyscrasia associated with ticlopidine therapy: Evidence for causality CMAJ 163 2000 1441 1448
36. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
37. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
38. J.A. Goldstein, and S.M. de Morais Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 4 1994 285 299
39. P.G. Steg, D.L. Bhatt, P.W. Wilson, R. D'Agostino Sr., E.M. Ohman, and J. Röther One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 2007 1197 1206